semaglutide patents Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Tirzepatide And Semaglutide: Experts Explain

Berberine is not a GLP-1 agonist

doi: 10.1186/s13046-022-02372-8 32 ZhuJFanJXiaYWangHLiYFengZ

Deviations from the recommended storage conditions can compromise the quality and potency of semaglutide, potentially putting patients at risk

Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases

But if you are one of the millions of people currently takingor consideringthese medications, you might have noticed the conversation shifting

Given that, the ideal diet should always include foods that naturally increase the release of GLP-1 hormone in the body: healthy fats like olive oil, fiber, and protein